(redirected from Ceclor cd)
Also found in: Dictionary.


a semisynthetic broad-spectrum second-generation cephalosporinantibiotic administered orally in treatment of otitis media and infections of the respiratory tract, urinary tract, and skin and soft tissues.


Apo-Cefaclor (CA), Distaclor (UK), PMS-Cefaclor (CA), Raniclor

Pharmacologic class: Second-generation cephalosporin

Therapeutic class: Anti-infective

Pregnancy risk category B


Interferes with bacterial cell-wall synthesis, causing cell to rupture and die


Capsules: 250 mg, 500 mg

Oral suspension: 125 mg/5 ml, 187 mg/5 ml, 250 mg/5 ml, 375 mg/5 ml

Tablets (extended-release): 500 mg

Indications and dosages

Uncomplicated skin infections caused by Staphylococcus aureus

Adults and children ages 16 and older: 375 mg P.O. (extended-release tablet) q 12 hours for 7 to 10 days

Pharyngitis and tonsillitis not caused by Haemophilus influenzae

Adults and children ages 16 and older: 375 mg P.O. (extended-release tablet) q 12 hours for 10 days

Chronic bronchitis and acute bronchitis not caused by H. influenzae

Adults and children ages 16 and older: 500 mg P.O. (extended-release tablet) q 12 hours for 7 days

Otitis media caused by staphylococci; lower respiratory tract infections caused by H. influenzae, S. pyogenes, and S. pneumoniae; pharyngitis and tonsillitis caused by S. pyogenes; urinary tract infections caused by Klebsiella species, Escherichia coli, Proteus mirabilis, and coagulase-negative staphylococci

Adults and children ages 13 to 17: 250 mg P.O. q 8 hours. For severe infections, 500 mg P.O. q 8 hours.

Children: 20 mg/kg/day P.O. in divided doses q 8 hours. For serious infections, 40 mg/kg/day P.O. in divided doses q 8 hours. Maximum dosage is 1 g/day.

Dosage adjustment

• Renal insufficiency
• Elderly patients


• Hypersensitivity to cephalosporins or penicillins


Use cautiously in:
• renal impairment, phenylketonuria
• history of GI disease (especially colitis)
• emaciated patients
• elderly patients
• pregnant or breastfeeding patients
• children.


• Obtain specimens for culture and sensitivity testing as necessary before starting therapy.
• Be aware that cross-sensitivity to penicillins may occur.
• Give extended-release tablets with food to enhance absorption.
• Don't give antacids within 2 hours of extended-release form.

Adverse reactions

CNS: headache, lethargy, paresthesia, syncope, seizures

CV: hypotension, palpitations, chest pain, vasodilation

EENT: hearing loss

GI: nausea, vomiting, diarrhea, abdominal cramps, oral candidiasis, pseudomembranous colitis

GU: vaginal candidiasis, nephrotoxicity

Hematologic: lymphocytosis, eosinophilia, bleeding tendency, hemolytic anemia, hypoprothrombinemia, neutropenia, thrombocytopenia, agranulocytosis, bone marrow depression

Hepatic: hepatic failure, hepatomegaly

Musculoskeletal: arthralgia

Respiratory: dyspnea

Skin: urticaria, maculopapular or erythematous rash

Other: chills, fever, superinfection, anaphylaxis, serum sickness


Drug-drug.Aminoglycosides, loop diuretics: increased risk of nephrotoxicity

Antacids: decreased absorption of extended-release cefaclor tablets

Chloramphenicol: antagonistic effect

Probenecid: decreased excretion and increased blood level of cefaclor

Drug-diagnostic tests.Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, creatinine, eosinophils, gamma-glutamyltransferase, lactate dehydrogenase: increased levels
Coombs' test, urinary 17-ketosteroids, nonenzyme-based urine glucose tests (such as Clinitest): false-positive results

Hemoglobin, platelets, white blood cells: decreased values

Patient monitoring

• Assess CBC and kidney and liver function test results.
• With long-term therapy, obtain monthly Coombs' test.
• Monitor for signs and symptoms of superinfection and other serious adverse reactions.

Patient teaching

• Instruct patient to take drug with food or milk to reduce GI upset.
• Advise patient to complete entire course of therapy even if he feels better.
• Tell patient to report signs and symptoms of allergic response and other adverse reactions, such as rash, easy bruising, bleeding, severe GI problems, or difficulty breathing.
• Instruct patient to avoid taking antacids within 2 hours of extended-release cefaclor.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.


/cef·a·clor/ (sef´ah-klor) a semisynthetic, second-generation cephalosporin effective against a wide range of gram-positive and gram-negative bacteria.


A broad-spectrum cephalosporin antibiotic, C15H14ClN3O4S, that is given orally.


a cephalosporin antibiotic.
indications It is prescribed in the treatment of selected infections caused by susceptible strains of bacteria.
contraindications Known hypersensitivity to cephalosporins prohibits its use. It is used with caution in patients who are allergic to penicillin.
adverse effects Among the most serious adverse reactions are hypersensitivity reactions and diarrhea, nausea, and vomiting.


A broad-spectrum antibiotic. One of the CEPHALOSPORINS that can be taken by mouth. Brand names are Distaclor and Keftid.

cefaclor (sef´əklor),

n brand names: Ceclor, Ceclor CD;
drug class: second-generation cephalosporin;
action: inhibits bacterial cell wall synthesis;
uses: eradication of gram-negative bacilli from the upper and lower respiratory tract and treatment of urinary tracts and skin infections and otitis media.


a second generation cephalosporin antibiotic, administered orally. Not widely used in veterinary medicine.
References in periodicals archive ?
24, 1998, Dura revealed that, due to weak sales of Ceclor CD, Keftab, Nasarel/Nasalide, Rondec and Dura-Vent, its 1stQ 1998 and 1998 results would be much worse than earlier forecast.
Our expeditious launch of Ceclor CD enabled us to bring the product to market in time for the start of the winter respiratory season and to make a strong impact, even though we were still building our marketing strength.
Besides producing sales growth, the addition of products such as Ceclor CD and Keftab enable Dura to expand its sales force to effectively launch its first Spiros(TM) product (albuterol), expected in late 1998," noted Garner.
Dura will begin promoting Keftab to physicians immediately after the transaction closes and will launch and promote Ceclor CD, which was cleared for marketing by the U.
Meanwhile, the promotion of Ceclor CD and Keftab by Dura will allow us to concentrate our efforts on maximizing the growth of Prozac(R) and our full complement of new products, including ReoPro(TM), Gemzar(R) and Humalog(R).
Ceclor CD, for which Lilly received marketing approval from the FDA in June and which Dura expects to launch this fall, will offer the advantage of twice-a-day dosing.
The addition of Ceclor CD and Keftab complements Dura's existing line of prescription products and is expected to have both strong strategic and positive financial impact.
Dura will begin promoting Keftab to physicians immediately after the transaction closes and will launch and vigorously promote Ceclor CD in time for the upcoming respiratory season.